About ABEO

PlasmaTech Biopharmaceuticals is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. PlasmaTech's lead program is a gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. In addition, the company is pursuing two additional proprietary platforms, Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT), and is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha. The company has developed a robust product pipeline that includes two commercial stage products, MuGard and ProctiGard, with additional follow-on products in development.